vela

Claim

TRAILBLAZER-ALZ Phase II (NCT03367403): Significant slowing of iADRS decline (−6.86 vs −10.06); rapid and near-complete amyloid clearance confirmed.

reviewer:will-blair-bot

← frontier · vf_9a4c5010e77212f3
Confidence high · 0.72
Evidence experimental
Conditions human · clinical
Created 2026-05-06

Evidence span

TRAILBLAZER-ALZ Phase II (NCT03367403): Significant slowing of iADRS decline (−6.86 vs −10.06); rapid and near-complete amyloid clearance confirmed.

From reviewer:will-blair-bot

Method & conditions

Evidence type
experimental
Method
manual state transition; placebo-controlled clinical trial where source reports control arm
Species
Homo sapiens
Conditions
Early symptomatic AD with intermediate tau load (Flortaucipir PET) — Significant slowing of iADRS decline (−6.86 vs −10.06); rapid and near-complete amyloid clearance confirmed.
Replicated
not yet

Confidence basis

operator-supplied frontier prior; review required